Skip to main content

Pfizer statistics

  • PFE · NYSE
  • Pharmaceuticals
  • S&P 500
$28.89+0.21%Close 13 Nov 2026

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Enterprise value$213.4B
EV / EBITDA10.60
EV / sales3.35

Share price

Latest close$28.89
Day's change+0.2%
52-week high$31.44
52-week low$23.62
From 52-week high−8.1%
Return · 1 month−2.3%
Return · 3 months+4.0%
Return · year to date+16.0%
Return · 1 year+11.7%
Beta · 1 year against the S&P 5000.26
50-day average$28.80
200-day average$26.98
RSI 1445.0
Average volume · 20 sessions35.2M

Margins and returns

For fiscal 2025, as filed.

Gross margin74.3%
Operating margin22.8%
Net margin12.4%
Free cash flow margin14.5%
Return on equity8.9%
Return on assets5.3%
Return on invested capital6.7%
Return on capital employed8.3%
Stock-based compensation / revenue1.3%

Financial position

At the end of fiscal 2025.

Cash and equivalents$1.14B
Total debt$67.42B
Net debt$53.82B
Current ratio1.16
Debt / equity0.78
Net debt / EBITDA2.58
Interest coverage5.33

Shares and dividends

For fiscal 2025, as filed.

Diluted shares5.7B
Dividends per share$1.72
Dividend payout126%

Taxes

For fiscal 2025, as filed.

Income tax expense−$266.0M
Effective tax rate−3.5%

PFE in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.